CNMD — CONMED Corporation

Summary of CONMED's Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Sales: $317 million, down 1.3% year-over-year. Excluding gastroenterology (GI) product exits, sales increased by 3.8% year-over-year.
• Adjusted Net Income: $27.1 million, a decrease of 8.5% year-over-year.
• Adjusted Diluted EPS: $0.89, down 6.3% year-over-year.
• Orthopedic Sales Growth: 4.5% in constant currency; General Surgery sales declined 7.4% in constant currency but were flat when adjusted for GI exits.
• Gross Margin: 57.4%, an increase of 100 basis points year-over-year.
• Cash Flow from Operations: $13.5 million, down from $41.5 million in Q1 2025.
• Long-term Debt: Increased to $860.2 million, with a leverage ratio of 3.1x.

2. Strategic Updates and Business Highlights

• Divestiture of GI Products: CONMED completed agreements to divest its GI product lines, allowing a strategic focus on higher-margin offerings in orthopedics and minimally invasive surgery.
• Key Growth Platforms: Emphasis on AirSeal (clinical insufflation), Buffalo Filter (smoke evacuation), and BioBrace (sports medicine).
  • AirSeal: Strong growth potential in robotic and laparoscopic surgery with an installed base of over 10,000 systems.
  • Buffalo Filter: Legislative support for smoke evacuation is growing, with 20 states enacting smoke-free operating room laws.
  • BioBrace: Recognized for its unique benefits in soft tissue repair, with ongoing clinical studies supporting its adoption.
• Supply Chain Improvements: Enhanced performance leading to consistent service levels and improved sales engagement.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Raised organic growth expectations to 5.0% - 6.5% from 4.5% - 6.0%. Expected reported revenue between $1.35 billion and $1.375 billion.
• Q2 Revenue Expectations: Anticipated revenue between $336 million and $340 million.
• Adjusted EPS Guidance: Maintained at $4.30 - $4.45 for the full year, with Q2 expected between $1.09 and $1.14.

4. Bad News, Challenges, or Points of Concern

• Sales Declines: Total sales decreased by 1.3%, with a notable decline in general surgery sales (8.5% drop).
• Interest Expense Increase: Anticipated refinancing of debt may lead to at least a $0.10 impact on adjusted EPS due to higher interest costs.
• Supply Chain Challenges: Although improvements have been made, there is still a risk of lag in recouping lost business due to previous supply chain issues.

5. Notable Q&A Insights

• Debt Refinancing Strategy: Management is focusing on bank debt over convertible notes due to unfavorable market conditions for the latter.
• Inflationary Pressures: Some commodity costs are rising, but management is actively working to mitigate these impacts on margins.
• Market Penetration for AirSeal: Currently at 6-7% in laparoscopic procedures, with efforts to increase standardization and adoption.
• Buffalo Filter OEM Business: Considered a smaller part of the overall smoke evacuation business, with expectations for it to diminish over time as focus shifts to direct sales.

Overall, CONMED is navigating through a transitional phase with strategic divestitures and a focus on core growth platforms, while facing challenges related to sales declines and rising costs.